The SS18-SSX fusion, a hallmark of SyS, alters gene expression and can enhance RTK activation [130]; this suggests that RTKs not only contribute independently to tumor biology but also interact with genetic alterations to drive malignancy [131]. The gene discussed is SARS2; the disease is neoplasm.